2022 Decisions

Opinions of the United
States Court of Appeals
for the Third Circuit

9-7-2022

Phyllis Bennett v. Teva Pharmaceuticals USA Inc

Follow this and additional works at: https://digitalcommons.law.villanova.edu/thirdcircuit_2022

Recommended Citation
"Phyllis Bennett v. Teva Pharmaceuticals USA Inc" (2022). 2022 Decisions. 691.
https://digitalcommons.law.villanova.edu/thirdcircuit_2022/691

This September is brought to you for free and open access by the Opinions of the United States Court of Appeals
for the Third Circuit at Villanova University Charles Widger School of Law Digital Repository. It has been accepted
for inclusion in 2022 Decisions by an authorized administrator of Villanova University Charles Widger School of Law
Digital Repository.

NOT PRECEDENTIAL
UNITED STATES COURT OF APPEALS
FOR THE THIRD CIRCUIT
_____________
Nos. 21-1642 & 21-2304
_____________

UNITED STATES COURT OF APPEALS
FOR THE THIRD CIRCUIT
_____________
Nos. 21-1642 & 21-2304
_____________
PHYLLIS BENNETT, Executor of the Estate of Harvey Bennett; ARTHUR J. OLSTAD;
KATHLEEN OLSTAD; ROBERT PERKINS; ELIZABETH CLARK; WILLIAM
MURPHY; BONNIE MURPHY; RITA WEAVER; MARVIN BAUMAN; ROWENA
BAUMAN; HENRY ACKERMAN; GENIEVE ACKERMAN; DONALD
HACKERSON; CAROLYN HACKERSON; JAMES WALZ; MARY BETH WALZ;
JUDITH COTE; THEODORE ALMOND; EDWARD J. MILLER, JR.; THOMAS
HEPLER; BARBARA KING; SAMUEL KING; RICKEY THOMAS; CAROLYN
THOMAS; JOHN ACKERMAN; KIM ACKERMAN; ALBERT DELSANTRO;
CHARLOTTE DELSANTRO; RICHARD BRESETTE; RALPH
BOOTH; HANS OMASTA; WINONA OMASTA; EDDIE BATES; LINDA BATES;
CHARLES DAVID SMEDLEY; MARCHETTE COOK, Personal Representative of the
Estate of Alice Southerland; TY BEARD; VERNON DEBOARD, Personal
Representative of the Estate of Katherine DeBoard; JOHN A. DAVIS, JR.; DEBORAH
DAVIS; KENNETH COLLINS; KIM COLLINS; CAROLYN HARRISON, Personal
Representative of the Estate of Gerald Harrison; KAY ANN RICE; ROBERT RICE;
LOIS RONCAL; DARLENE HERONEMA; KATHERINE WOLLASTON; DANIEL
WOLLASTON; GEORGE CHOSICH; ELIZABETH CHOSICH; PEGGY BROWN;
MARY ANN MINASIAN; LEE ALVIN SMITH; MARY PARKER; BRIAN
SUKENIK; LINDA BRUNNER; DENNIS WORKMAN; MARY WATERS; GEORGE
SCHMIDT; SHARON SCHMIDT; CLINTON HUMPHREY; TENNA HUMPHREY;
BETTY BOSTIC; JIMMY BOSTIC; GEORGIA SUTTON; BRAHA JACKSON;
ROBERT MASON; NOEL CLECKLER; FRANCES CLECKLER; MARK
LAGANELLI, Personal Representative of the Estate of Lawrence Laganelli; NEILS
DAVIS; DON AMBURGEY; JOYCE AMBURGEY; ELBERT CROWDER;
TIMOTHY LEROSE; MARGARET LEROSE; DOYLE TURNER, Personal
Representative of the Estate of Carolyn Turner; MELVIN KINNEY; ISABELLA

KINNEY; BALDEMAR MARTINEZ; ANNA MARTINEZ; ALBERT SHEPHERD,
Personal Representative of the Estate of Emily Shepherd; DORIS JOHNSON; FRED
BURROUGH; MONA WINDHAM; RONNIE WINDHAM; WILLIAM HUNT;
PHYLLIS HUNT; PINK JONES; ANNIE JONES; MARY DAVIS; JAMES MASON;
CATHY MASON; CECIL THOMAS; DEBBIE THOMAS; MARTHA SUE DIXON;
BELVA WARD; DONALD BARD; JUDY BARD; JOHN SPAULDING, JR.; LINDA
SPAULDING; SHIRLEY MILLER; RONALD MILLER; JACQUELINE FABBRI,
Personal Representative of the Estate of Frank Fabbri; INGA REYNOLDS, Personal
Representative of the Estate of Gerwin Hermenau; CARLETTA WILLIAMS, Personal
Representative of the Estate of James C. Williams, III; TRIO CALDWELL; BEVERLY
CALDWELL; EDWIN STREED; MARGARET STREED; DIANNE CRUCE; DOUG
HYAK; DAMEON ALBRITTON; JI YONG AHN ALBRITTON; LAUREL TURLEY;
ROGER TURLEY; DIANE MANCINELLI; CONNIE LUYE, Personal Representative
of the Estate of Evelyn Moss; ROBERT E. SMITH; DORLIS LYLE, Personal
Representative of the Estate of James Lyle; GEORGE L. BUSH; EDWIN MARTIN;
CHARLES HERSHISER; MARY FRANCES HERSHISER; SHELBY CAMPBELL;
PENNY WATSON, Personal Representative of the Estate of Darwin Watson; JOHN
HENDRIX; LINDA PERRY,
Appellants in No. 21-1642
JAMES JORDAN; SHARON JORDAN; BOBBY HUGHES, PERSONAL
REPRESENTATIVE OF THE ESTATE OF MIRIAM HUGHES; BILLY KARR;
SHANNON DAY; CINDY DAY; PATRICIA ALBRECHT RHODES, PERSONAL
REPRESENTATIVE OF THE ESTATE OF REX RHODES; BRUCE WEHLING,
PERSONAL REPRESENTATIVE OF THE ESTATE OF LEONARD WEHLING, JR.,
Appellants in No.21-2304
v.
TEVA PHARMACEUTICALS USA INC
_____________
ON APPEAL FROM THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE
(D.C. Civil Nos. 1-19-cv-02126 and 1-20-cv-01209)
District Judge: Honorable Colm F. Connolly
_____________
Argued May 4, 2022
_____________
2

Before: CHAGARES, Chief Judge, GREENAWAY, JR. and PORTER, Circuit Judges
(Opinion Filed: September 7, 2022)
Samuel C. Cole
[ARGUED]
4421 Kelly Drive
Richardson, TX 75082
Edward K. Wood, Jr.
Wood Law Firm
P.O. Box 382434
Birmingham, AL 35238
Counsel for Appellants
Jaime A. Santos
[ARGUED]
Goodwin Procter
1900 N Street, N.W.
Washington, DC 20036
Carla R. Karp
Greenberg Traurig
500 Campus Drive
Suite 400
Florham Park, NJ 07932
Glenn S. Kerner
Greenberg Traurig
One Vanderbilt Avenue
New York, NY 10017
Counsel for Appellee
_____________
OPINION
______________



This disposition is not an opinion of the full Court and, pursuant to I.O.P. 5.7, does not
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GREENAWAY, JR., Circuit Judge.
Prescription drugs are generally a boon to the health of our populace. Their ability
to address maladies is something we have accepted and embraced societally. But
unfortunately, prescription drugs often carry a risk of side effects. That risk—and a
pharmaceutical company’s obligation to warn of the risk of side effects—gives rise to
this litigation.
Amiodarone, which is manufactured by Teva Pharmaceuticals USA Inc. (“Teva”
or “Appellee”), is a generic version of a prescription drug named Cordarone (produced by
Wyeth Pharmaceuticals). Appellants are patients, spouses, heirs, and the estates of
decedents who used the drug for its off-label use to treat atrial fibrillation (“a-fib”). They
commenced two actions against Teva relating to Teva’s manufacture and distribution of
Amiodarone.
Appellants allege Teva violated its state law duties, as a generic manufacturer, to
warn users regarding Amiodarone’s off-label use. Specifically, Teva did not provide
federally mandated Medication Guides, and it failed to report all adverse events to the
FDA. Also, according to Appellants, Teva either directly or through omission
misrepresented that Amiodarone was safe and effective as a treatment for a-fib.
In this consolidated appeal, we will affirm the District Court’s dismissal of
Appellants’ claims because Appellants fail to adhere to the requirements of Rules 8 and 9
of the Federal Rules of Civil Procedure.
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BACKGROUND
A.

Statutory and Regulatory Framework

The Food, Drug, and Cosmetic Act (“FDCA”), Ch. 675, 52 Stat. 1040 (codified as
amended at 21 U.S.C. § 301 et seq.), provides the regulatory framework for prescription
drugs in the United States. Under the FDCA, drug manufacturers must seek approval
from the United States Food and Drug Administration (“FDA”) to bring a new drug to
market. The approval processes for brand-name drugs and generic drugs differ
significantly.
Brand-name drug manufacturers must first file a New Drug Application. 21
U.S.C. § 355(b)(1), (d). Thereafter, they must prove the drug’s safety and efficacy and
propose accurate and adequate labeling. Id. “As the Supreme Court has recognized,
‘[m]eeting those requirements involves costly and lengthy clinical testing.’” In re
Fosamax (Alendronate Sodium) Prod. Liab. Litig. (No. II), 751 F.3d 150, 153 (3d Cir.
2014) (quoting PLIVA, Inc. v. Mensing, 564 U.S. 604, 612 (2011)).
By contrast, pursuant to the Drug Price Competition and Patent Term Restoration
Act of 1984 (the “Hatch-Waxman Act”), codified at 21 U.S.C. §§ 355, 360cc and
35 U.S.C. §§ 156, 271, 282, generic drugs can “gain FDA approval simply by showing
equivalence to a . . . drug that has already been approved by the FDA.” In re Fosamax,
751 F.3d at 153 (quoting Mensing, 564 U.S. at 612); see also 21 U.S.C. § 355(j)(2)(A)).
To do so, generic drug manufacturers must file an Abbreviated New Drug Application.
The FDA will provide its approval if the generic drug manufacturer sufficiently
demonstrates that “the generic drug and the FDA-approved brand-name drug are
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bioequivalent[, and] . . . hav[e] the same active ingredients, . . . route of administration,
dosage form, dosage form, dosage strength, and labeling.” In re Fosamax, 751 F.3d at
153 (citing 21 U.S.C. § 355(j)(2)(A)(ii)-(v)). The purpose of the Hatch-Waxman Act is
to “allow[ ] manufacturers to develop generic drugs inexpensively, without duplicating
the clinical trials already performed on the equivalent brand-name drug.” Id. (quoting
Mensing, 564 U.S. at 612.).
For drugs with serious side effects, the FDA also requires patient labeling.
21 C.F.R. § 208.1(c) (“Patient labeling will be required if the FDA determines that . . .
[t]he drug product is one for which patient labeling could help prevent serious adverse
effects.”). For those drugs, the manufacturer must provide Medication Guides or the
means to produce them to distributors, packers, or authorized dispensers. 21 C.F.R.
§ 208.24(b).1 In turn, distributors or packers must provide those guides or the means to
produce them to authorized dispensers. 21 C.F.R. § 208.24(c). At the time that a drug is
dispensed, these dispensers must then provide the Medication Guide to patients or their
agents. 21 C.F.R. § 208.24(e). The FDA approves Medication Guides “to ensure [they

Specifically, § 208.24(b) provides: “[e]ach manufacturer who ships a container of drug
product for which a Medication Guide . . . is responsible for ensuring that Medication
Guides are available for distribution to patients by either: (1) [p]roviding Medication
Guides in sufficient numbers to distributors, packers, or authorized dispensers to permit
the authorized dispenser to provide a Medication Guide to each patient receiving a
prescription for the drug product; or (2) [p]roviding the means to produce Medication
Guides in sufficient numbers to distributors, packers, or authorized dispensers to permit
the authorized dispenser to provide a Medication Guide to each patient receiving a
prescription for the drug product.”
1
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are] consistent with [the information contained] in the package insert.” 63 Fed. Reg. at
66386.
Beyond drug approval and labeling, the FDCA and FDA impose other
requirements. As relevant here, the FDCA “generally prohibits manufacturers from
marketing, advertising, or otherwise promoting drugs for . . . unapproved or ‘off-label’
uses” (i.e., “therapeutic uses other than their FDA-approved indications”). In re Schering
Plough Corp. Intron/Temodar Consumer Class Action, 678 F.3d 235, 239–40 (3d Cir.
2012) (citing 21 U.S.C. § 331(a) and (d)). However, because “the FDCA does not
regulate the practice of medicine, physicians may lawfully prescribe drugs for [such] offlabel uses.” Id. (citation omitted). Drug manufacturers must also report adverse drug
experiences to the agency.2 21 C.F.R. § 314.80(c). Pursuant to Section 314.80, adverse
drug experiences are defined as “[a]ny adverse event associated with the use of a drug in
humans, whether or not considered drug related.” Id.
B.

Factual and Procedural History

Appellants either are patients who were injured by the drug Amiodarone or sue on
behalf of their relatives who were injured by the drug Amiodarone. Although the facts
differ slightly among them, the general allegations are the same. Each patient suffered
from a-fib and was prescribed Amiodarone. Appellants allege that the patients suffered

Examples of adverse drug experiences include: “[a]n adverse event occurring in the
course of the use of a drug product in professional practice; an adverse event occurring
from drug overdose whether accidental or intentional; an adverse event occurring from
drug abuse; an adverse event occurring from drug withdrawal; and any failure of
expected pharmacological action.” 21 C.F.R. § 314.80(a).
2
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significant side effects (such as pulmonary fibrosis, pulmonary toxicity, and respiratory
failure) as a result of using Amiodarone, including, in some cases, death.
Amiodarone is the generic form of the brand-name drug Cordarone. Teva is a
manufacturer of generic Amiodarone. Amiodarone is a drug of “last resort” for patients
suffering from ventricular fibrillation and tachycardia. Appendix (“App.”) 322. The
FDA has not approved Amiodarone for the treatment of a-fib, but physicians prescribe it
for this “off-label” purpose. App. 58.
The plaintiffs bring seven claims under Delaware state law: strict liability and
negligent failure to warn (Counts 1–2); negligent marketing and sale (Count 3);
negligence per se (Count 4); strict liability for defective manufacturing under Del. Code
§ 3302 (Count 5); fraud (Count 6); and a derivative claim for wrongful death (Count 7).
Appellants’ claims broadly fall into three theories of liability. First, Appellants allege
that they did not receive Medication Guides when their Amiodarone prescriptions were
dispensed, as required by federal regulations, because Teva failed to make them available
to pharmacists in sufficient numbers. Second, Appellants allege that Teva failed to report
known adverse events to the FDA. Third, Appellants allege that Teva negligently and
fraudulently promoted Amiodarone as approved for the treatment of a-fib or benefitted
from others’ fraudulent promotion of the off-label use of the drug.
Teva moved to dismiss both cases pursuant to Federal Rule of Civil Procedure
12(b)(6). The District Court granted both motions, holding that the plaintiffs’ claims
were impliedly preempted by the FDCA. In opposing the motions to dismiss, Appellants
concluded by briefly requesting leave to amend their complaints should the District Court
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be inclined to grant the motions. However, because the District Court held that the
claims were preempted as a matter of law, the court dismissed both complaints with
prejudice. Appellants timely appealed. This Court consolidated the appeals on July 21,
2021. Appellants in Jordan v. Teva Pharmaceuticals USA Inc, No. 21-2304, adopted the
brief filed by Appellants in Bennett v. Teva Pharmaceuticals USA, Inc., No. 21-1642, on
October 19, 2021.
After observing a potential issue regarding the District Court’s subject matter
jurisdiction over these cases, we remanded the orders of the District Court. Specifically,
we instructed the District Court to consider whether the Doe defendants were merely
nominal defendants that may be dismissed without prejudice or whether to permit the
Appellants to amend the Bennett complaint to assert jurisdiction under CAFA.
Subsequently, the parties filed a joint motion to dismiss the Doe defendants and a petition
for rehearing. We granted both requests on August 26, 2022, and now reach the merits.
STANDARD OF REVIEW
We review “a district court’s decision granting a party’s motion to dismiss de
novo.” Buck v. Hampton Twp. Sch. Dist., 452 F.3d 256, 260 (3d Cir. 2006). “To survive
a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true,
to state a claim to relief that is plausible on its face.” Zuber v. Boscov’s, 871 F.3d 255,
258 (3d Cir. 2017) (quoting Santiago v. Warminster Twp., 629 F.3d 121, 128 (3d Cir.
2010)). “A claim has facial plausibility when the plaintiff pleads factual content that
allows the court to draw the reasonable inference that the defendant is liable for the
misconduct alleged.” Id. (quoting Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009)).
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Pursuant to Rule 8 of the Federal Rules of Civil Procedure, a plaintiff is required
to provide “a short and plain statement of the claim showing that the pleader is entitled to
relief.” Fed. R. Civ. P. 8(a)(2). In addition, under Rule 9, fraud claims are subject to a
heightened pleading standard. Fed. R. Civ. P. 9(b); see also In re Burlington Coat
Factory Sec. Litig., 114 F.3d 1410, 1418 (3d Cir. 1997) (citation omitted) (“boilerplate
and conclusory allegations will not suffice” and “[p]laintiffs must accompany their legal
theory with factual allegations that make their theoretically viable claim plausible.”).
DISCUSSION
As a preliminary matter, we shall address whether Appellants’ claims are
sufficiently pled pursuant to Rules 8 and 9. “[A]lthough the District Court did not
address [the sufficiency of the pleadings], we can affirm based on any grounds supported
by the record.” Ridley Sch. Dist. v. M.R., 680 F.3d 260, 282 (3d Cir. 2012) (citing
Chambers ex rel. Chambers v. Sch. Dist. Of Philadelphia Bd Of Educ., 587 F.3d 176,
183–34 (3d Cir. 2009)).
A.

Medication Guide Claim

Appellants allege that “Defendants failed to ensure the Medication Guide was
provided to all consumers, including Plaintiffs, in the manner required by law.” App. 352
¶ 188. Not only is this allegation conclusory insofar as it fails to articulate how Teva’s
provision of the Medication Guide was purportedly deficient, see Iqbal, 556 U.S. at 678,
but also 21 C.F.R. § 208.24(b)(2) does not impose a requirement that drug manufacturers
deliver Medication Guides directly to patients. Rather, § 208.24 permits manufacturers
to “[p]rovid[e] the means to produce Medication Guides in sufficient numbers to
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distributors, packers, or authorized dispensers.” 21 C.F.R. § 208.24(b). Appellants make
no factual allegations that support the inference that Appellee failed to do so. Thus, their
Medication Guide claim is not plausibly alleged.
B.

Failure to Report Claim

Appellants allege “Defendants also failed to report thousands of serious adverse
medical events in their exclusive possession to the FDA, health care professionals, and
consumers, including Plaintiffs.” App. 352. These pleadings are conclusory. Appellants
cannot rely on the assumption that because millions of patients are diagnosed with a-fib
and Amiodarone is prescribed off-label to treat it, Appellee failed to report or otherwise
concealed adverse events. At the very least, Appellants would need to provide examples
of countless adverse events that Appellee knew or should have reasonably known about
but failed to report to the FDA. Appellants’ failure to sufficiently plead such claims
necessarily means that their pleadings, to the extent they allege fraud, likewise fail to
satisfy the heighted pleading standard of Rule 9.
C.

Off-Label Promotion Claim

Appellants allege “Teva ‘provided or failed to correct false and misleading
information about the indications and uses of Amiodarone provided to physicians via
reference materials like the PDR and Epocrates, that are used by physicians in prescribing
situations and which the prescribing physicians read and rely on in prescribing
Amiodarone to Plaintiffs.’” Appellants’ Br. at 49 (citing App. 363). Such allegations are
similarly insufficient under Rule 9’s heightened pleading standard. Appellants do not
identify any specific misrepresentations and instead, generally assert that the information
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provided in the reference materials, which Appellants characterize as labeling, was false
and misleading.
In addition, Appellants do not plead sufficient factual allegations to support the
inference that Teva is responsible for or otherwise contributed to these reference
materials. Teva, as a generic drug manufacturer, does not have any control over
labeling—that was solely Wyeth’s responsibility. See Mensing, 564 U.S. at 613 (citation
omitted) (explaining that a generic drug manufacturer must “ensur[e] that its warning
label is the same as the brand name’s”).
D.

Leave to Amend

Although Rule 15 provides that leave to amend should be “freely give[n] when
justice so requires,” we will not grant Appellants leave in this case. Fed. R. Civ. P.
15(a)(2). Where, as here, a plaintiff includes a “single sentence, lacking a statement for
the grounds for amendment and dangling at the end of her memorandum” in opposition to
a motion to dismiss, “a motion for leave to amend was never properly before [the District
Court].” Ramsgate Ct. Townhome Ass’n v. W. Chester Borough, 313 F.3d 157, 161 (3d
Cir. 2002). Thus, the District Court did not abuse its discretion when it dismissed
Appellants’ claims with prejudice.
CONCLUSION
For the foregoing reasons, we will affirm the District Court’s dismissal of
Appellants’ complaints.
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